Ticlopidine effects on constitutive hGPR17 activity
Cell-based study · HEK293 cells transiently transfected with Gqi4myr, CREB-Luc reporter plasmid and receptor or pcDNA3; hGPR17 isoforms [1]
HEK293 cells transiently transfected with hGPR17 isoforms and a CREB-Luc reporter were incubated with varying concentrations of Ticlopidine. Ticlopidine did not suppress the constitutive activity of any hGPR17 isoform.
| Endpoint | Reported result | Reference |
|---|---|---|
| CREB activity | Reported result Ticlopidine did not suppress the constitutive activity of any of the hGPR17 isoforms | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- varying concentrations
- Exposure duration
- 24 h before substrate addition
- Method
- incubated with the ligand
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Ticlopidine
The paper names Ticlopidine without stating the salt or form; not verified as the hydrochloride form supplied as A11690. No dose conversion or lot validation.
Methods > cAMP response element binding protein trans-reporter luciferase assay (S44, S47); Results > The uracil nucleotides UDP-glucose, UDP-galactose and UDP activate hGPR17-S and -L with different potencies (S154); Figure 6 legend (S255, S256, S257, S258)
CREB activity: CREB activity; comparator: activity in absence of the ligand — Methods > cAMP response element binding protein trans-reporter luciferase assay (S44); Results > The uracil nucleotides UDP-glucose, UDP-galactose and UDP activate hGPR17-S and -L with different potencies (S154)